Cargando…
Growth and Overall Health of Patients with SLC13A5 Citrate Transporter Disorder
We were interested in elucidating the non-neurologic health of patients with autosomal recessive SLC13A5 Citrate Transporter (NaCT) Disorder. Multiple variants have been reported that cause a loss of transporter activity, resulting in significant neurologic impairment, including seizures, as well as...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625967/ https://www.ncbi.nlm.nih.gov/pubmed/34822404 http://dx.doi.org/10.3390/metabo11110746 |
_version_ | 1784606551107960832 |
---|---|
author | Brown, Tanya L. Nye, Kimberly L. Porter, Brenda E. |
author_facet | Brown, Tanya L. Nye, Kimberly L. Porter, Brenda E. |
author_sort | Brown, Tanya L. |
collection | PubMed |
description | We were interested in elucidating the non-neurologic health of patients with autosomal recessive SLC13A5 Citrate Transporter (NaCT) Disorder. Multiple variants have been reported that cause a loss of transporter activity, resulting in significant neurologic impairment, including seizures, as well as motor and cognitive dysfunction. Additionally, most patients lack tooth enamel (amelogenesis imperfecta). However, patients have not had their overall health and growth described in detail. Here we characterized the non-neurologic health of 15 patients with medical records uploaded to Ciitizen, a cloud-based patient medical records portal. Ciitizen used a query method for data extraction. Overall, the patients’ records suggested a moderate number of gastrointestinal issues related to feeding, reflux, vomiting and weight gain and a diverse number of respiratory complaints. Other organ systems had single or no abnormal diagnoses, including liver, renal and cardiac. Growth parameters were mostly in the normal range during early life, with a trend toward slower growth in the few adolescent patients with data available. The gastrointestinal and pulmonary issues may at least partially be explained by the severity of the neurologic disorder. More data are needed to clarify if growth is impacted during adolescence and if adult patients develop or are protected from non-neurologic disorders. |
format | Online Article Text |
id | pubmed-8625967 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86259672021-11-27 Growth and Overall Health of Patients with SLC13A5 Citrate Transporter Disorder Brown, Tanya L. Nye, Kimberly L. Porter, Brenda E. Metabolites Article We were interested in elucidating the non-neurologic health of patients with autosomal recessive SLC13A5 Citrate Transporter (NaCT) Disorder. Multiple variants have been reported that cause a loss of transporter activity, resulting in significant neurologic impairment, including seizures, as well as motor and cognitive dysfunction. Additionally, most patients lack tooth enamel (amelogenesis imperfecta). However, patients have not had their overall health and growth described in detail. Here we characterized the non-neurologic health of 15 patients with medical records uploaded to Ciitizen, a cloud-based patient medical records portal. Ciitizen used a query method for data extraction. Overall, the patients’ records suggested a moderate number of gastrointestinal issues related to feeding, reflux, vomiting and weight gain and a diverse number of respiratory complaints. Other organ systems had single or no abnormal diagnoses, including liver, renal and cardiac. Growth parameters were mostly in the normal range during early life, with a trend toward slower growth in the few adolescent patients with data available. The gastrointestinal and pulmonary issues may at least partially be explained by the severity of the neurologic disorder. More data are needed to clarify if growth is impacted during adolescence and if adult patients develop or are protected from non-neurologic disorders. MDPI 2021-10-29 /pmc/articles/PMC8625967/ /pubmed/34822404 http://dx.doi.org/10.3390/metabo11110746 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Brown, Tanya L. Nye, Kimberly L. Porter, Brenda E. Growth and Overall Health of Patients with SLC13A5 Citrate Transporter Disorder |
title | Growth and Overall Health of Patients with SLC13A5 Citrate Transporter Disorder |
title_full | Growth and Overall Health of Patients with SLC13A5 Citrate Transporter Disorder |
title_fullStr | Growth and Overall Health of Patients with SLC13A5 Citrate Transporter Disorder |
title_full_unstemmed | Growth and Overall Health of Patients with SLC13A5 Citrate Transporter Disorder |
title_short | Growth and Overall Health of Patients with SLC13A5 Citrate Transporter Disorder |
title_sort | growth and overall health of patients with slc13a5 citrate transporter disorder |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625967/ https://www.ncbi.nlm.nih.gov/pubmed/34822404 http://dx.doi.org/10.3390/metabo11110746 |
work_keys_str_mv | AT browntanyal growthandoverallhealthofpatientswithslc13a5citratetransporterdisorder AT nyekimberlyl growthandoverallhealthofpatientswithslc13a5citratetransporterdisorder AT porterbrendae growthandoverallhealthofpatientswithslc13a5citratetransporterdisorder |